

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

REC'D 08 DEC 2004

WPO

PCT

Applicant's or agent's file reference 115566/bal	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416).
International Application No. PCT/AU2003/001004	International Filing Date (day/month/year) 8 August 2003	Priority Date (day/month/year) 9 August 2002
International Patent Classification (IPC) or national classification and IPC Int. Cl. 7 A61F 11/00, A61B 17/56		
Applicant COCHLEAR LIMITED et al		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.																
2. This REPORT consists of a total of 3 sheets, including this cover sheet. <input type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT). These annexes consist of a total of sheet(s).																
3. This report contains indications relating to the following items: <table> <tr><td>I</td><td><input checked="" type="checkbox"/> Basis of the report</td></tr> <tr><td>II</td><td><input type="checkbox"/> Priority</td></tr> <tr><td>III</td><td><input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</td></tr> <tr><td>IV</td><td><input type="checkbox"/> Lack of unity of invention</td></tr> <tr><td>V</td><td><input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</td></tr> <tr><td>VI</td><td><input type="checkbox"/> Certain documents cited</td></tr> <tr><td>VII</td><td><input type="checkbox"/> Certain defects in the international application</td></tr> <tr><td>VIII</td><td><input type="checkbox"/> Certain observations on the international application</td></tr> </table>	I	<input checked="" type="checkbox"/> Basis of the report	II	<input type="checkbox"/> Priority	III	<input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability	IV	<input type="checkbox"/> Lack of unity of invention	V	<input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement	VI	<input type="checkbox"/> Certain documents cited	VII	<input type="checkbox"/> Certain defects in the international application	VIII	<input type="checkbox"/> Certain observations on the international application
I	<input checked="" type="checkbox"/> Basis of the report															
II	<input type="checkbox"/> Priority															
III	<input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability															
IV	<input type="checkbox"/> Lack of unity of invention															
V	<input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement															
VI	<input type="checkbox"/> Certain documents cited															
VII	<input type="checkbox"/> Certain defects in the international application															
VIII	<input type="checkbox"/> Certain observations on the international application															

Date of submission of the demand 2 December 2003	Date of completion of the report 22 November 2004
Name and mailing address of the IPEA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaaustralia.gov.au Facsimile No. (02) 6285 3929	Authorized Officer XAVIER GISZ Telephone No. (02) 6283 2064

I. Basis of the report

1. With regard to the elements of the international application:*

the international application as originally filed.

the description, pages , as originally filed,
pages , filed with the demand,
pages , received on with the letter of

the claims, pages , as originally filed,
pages , as amended (together with any statement) under Article 19,
pages , filed with the demand,
pages , received on with the letter of

the drawings, pages , as originally filed,
pages , filed with the demand,
pages , received on with the letter of

the sequence listing part of the description:
pages , as originally filed
pages , filed with the demand
pages , received on with the letter of

REC'D 10 DEC 2004

CDMA PCT

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language which is:

the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).

the language of publication of the international application (under Rule 48.3(b)).

the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

contained in the international application in written form.

filed together with the international application in computer readable form.

furnished subsequently to this Authority in written form.

furnished subsequently to this Authority in computer readable form.

The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

4. The amendments have resulted in the cancellation of:

the description, pages

the claims, Nos.

the drawings, sheets/fig.

5. This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims 12-14, 17, 20-22	YES
	Claims 1-11, 15, 16, 18, 19, 23-25	NO
Inventive step (IS)	Claims	YES
	Claims 1-25	NO
Industrial applicability (IA)	Claims 1-25	YES
	Claims	NO

2. Citations and explanations (Rule 70.7)

The following documents identified in the International Search Report have been considered for the purposes of this report:

D1....US 5,906,635
D2....US 6,427,086

Novelty (N) Claims 1-11, 15, 16, 18, 19, 23-25

Claims 1-5, 7, 8, 10, 11, 18, 23: D1 discloses an implantable hearing aid device comprising a hermetically sealed component (68) mounted by screws extending through tabs (70) (figures 7, 8 and 9 and column 8 lines 60 to 62).

Claims 1-3, 5-9, 15, 16, 19, 23-25: D2 discloses an intracranial neurostimulator comprising a control module (620) with flexible flanges (632) mounted into the cranium by bone screws (623) (column 35 lines 5 to 16).

Inventive Step (IS) Claims 1-25

Claims 1-11, 15, 16, 18, 19, 23-25 also lack an inventive step for the reasons given above.

Claims 12-14, 17, 20-22: The features in these claims would all be arrived at as a matter of routine to a PSA in light of D1 or D2 and consequently lack inventive step.